Anzeige
Mehr »
Login
Donnerstag, 16.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
Letzte Chance, bevor die Bohrer dieses "Monster"-Vorkommen bei einem 13-Millionen-Unternehmen ansteuern
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
138 Leser
Artikel bewerten:
(0)

SciChart: From Data to Movement: The Breakthrough Helping Paralyzed Patients Walk Again

Finanznachrichten News

NeuroRestore combines cutting-edge spinal stimulation and real-time data visualization powered by SciChart to restore mobility for paralyzed patients, supported by $50 million in new funding

LONDON, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Imagine being told you'll never walk again. For millions with spinal cord injuries, this devastating reality is being rewritten. NeuroRestore, powered by SciChart's real-time data visualization, is transforming lives with groundbreaking spinal stimulation therapies that restore mobility and independence.

Backed by a $50 million investment from Ottobock, a global leader in medical technology, these revolutionary treatments are advancing toward commercialization, offering hope to patients worldwide.

The Science Behind the Breakthrough
Spinal cord injuries disrupt communication between the brain and body, leaving neural circuits dormant but intact. NeuroRestore reawakens these pathways by delivering precise electrical pulses that mimic natural brain signals, reengaging motor neurons. Real-time monitoring and advanced visualization tools allow clinicians to tailor treatments dynamically, identifying and activating dormant neural circuits for optimal recovery.

This groundbreaking combination of targeted stimulation and iterative feedback loops has already delivered life-changing results, demonstrating the potential of personalized neurorehabilitation.

Patient's progress during Epidural Electrical Stimulation (EES) therapy, visualized with NeuroRestore powered by SciChart, showing walking stages and

From Data to Recovery: The Role of SciChart
Restoring mobility to paralyzed patients requires synchronizing complex physiological data with precise electrical stimulation. Traditional tools often fall short in such demanding applications. SciChart bridges this gap with its proprietary rendering engine and real-time visualization capabilities, empowering clinicians to:

  • Instantly visualize neural activity, including muscle responses and stimulation waveforms.
  • Adjust parameters in real time, helping patients regain basic motor functions, such as standing, on their first day of therapy.
  • Process data from up to 16 EMG sensors simultaneously without latency or slowdowns.

Patient's progress during Epidural Electrical Stimulation (EES) therapy, visualized with NeuroRestore powered by SciChart, showing walking stages and

"SciChart's speed and thorough documentation have been crucial in advancing our therapy, enabling us to efficiently monitor numerous physiological signals without system slowdowns," said Charles David Sasportes, Lausanne University Hospital.

From Wheels to Steps: A Patient's Journey

Patient transitioning from a wheelchair to walking with a walker, showcasing NeuroRestore rehabilitation powered by SciChart.

For Michel Roccati, who was paralyzed after a motorcycle accident, NeuroRestore's technology provided a life-changing breakthrough. With cutting-edge implants and SciChart-powered real-time visualization, Michel took his first steps after years in a wheelchair.

"Walking is super important. I just stand up, can solve a lot of problems in normal life. With the walker, I'm free. I can walk wherever I want," said Michel.

This milestone underscores the independence and hope NeuroRestore's therapies bring to patients worldwide.

Beyond Paralysis: Expanding Horizons
NeuroRestore's journey is just one example of the innovation SciChart supports. While NeuroRestore explores therapies for stroke rehabilitation, Parkinson's disease, and neuroprosthetics, SciChart continues its own mission of enabling medtech companies to pioneer life-changing technologies. Its real-time data visualization tools empower researchers and clinicians to develop breakthroughs in diagnostics, patient monitoring, and personalized care.

"Healthcare is about people, not just numbers,"?says Andrew Burnett-Thompson SciChart CEO.?"Our mission is to empower clinicians with the tools they need to turn complex data into life-saving decisions."

For a closer look at this inspiring journey and the technology making it possible, watch the full story here: https://youtu.be/dKWON4ijYuw.

About SciChart

SciChart is a global leader in high-performance data visualization software, delivering the fastest, high-precision charts for complex, real-time applications. Its proprietary Vx Engine provides unmatched speed, flexibility, and precision. Trusted by industries like aerospace, healthcare, finance, and scientific research, SciChart supports cross-platform development for WPF, iOS, Android, JavaScript, and Linux. SciChart's award-winning technology powers mission-critical solutions worldwide, rendering millions of data points in real time.

To learn more, visit www.scichart.com.

Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/3f4f1e26-4bd2-4ff7-8d7e-4742e512190e
https://www.globenewswire.com/NewsRoom/AttachmentNg/0218c4fb-9840-477e-a6bd-2167fe710d3f
https://www.globenewswire.com/NewsRoom/AttachmentNg/a7892a08-6de8-4fee-a395-1b89617006ab


© 2025 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.